Skip to main content
IMMXImmix Biopharma, Inc.Sell4.9·$6.96
IMMX · Why this verdict

Why Immix Biopharma (IMMX) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Immix Biopharma is a cash-burning, single-pipeline biotech with weak quality scores and high short interest, offering binary upside only if its lead program delivers.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The pipeline rests on one asset, NXC-201, which is made by third-party CMOs, concentrating both clinical and supply risk.

↑Improving
Bear case
Expectation
NXC-201 advances without manufacturing disruption over the next 12 months.

CounterOutsourced manufacturing and a single-asset pipeline mean one clinical or supply setback could erase most of the company's value.

The business is cash-burning with negative FCF and a quality score of 1.6, below the 4.0 floor.

→Stable
Quality breakdown
Expectation
Quality score improves above 4.0 only if the company funds operations without heavy dilution.

CounterFor a pre-revenue biotech, negative FCF is normal and the quality score understates clinical value.

Quarterly EPS has landed in line with estimates, with the latest actual loss of -0.19 matching the -0.19 estimate.

↓Deteriorating
Earnings
Expectation
Quarterly loss stays near -0.19 per share, showing a controlled burn rate.

CounterIn-line losses still mean continuous cash burn that must be funded by new capital.

Short interest of 16% is high, signaling sizeable bearish positioning against the stock.

↑Improving
Key risks
Expectation
Short interest declines as clinical evidence accumulates.

CounterHigh short interest can fuel a squeeze if the lead program reads out well.

Price is below the 200-day average, but that average is still rising at +4.3%/30d, a pullback in an uptrend after a -54% drawdown.

↓Deteriorating
Momentum breakdown
Expectation
Price reclaims the 200-day average while its slope stays positive.

CounterFalling on-balance volume shows distribution, and the momentum score of 3.4 reflects persistent selling.

Per-dimension breakdown

Value

5.0/10data confidence 50%

Quality

1.6/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin0.0
Op margin0.0
Net margin0.0
Current ratio5.0
FCF quality0.0
Moat4.8
Piotroski F4.4
  • ▸Cash-burning (FCF negative)
  • ▸No competitive moat
  • ▸Quality concerns

Growth

5.0/10data confidence 50%

Momentum

3.4/10data confidence 100%
ComponentSub-score
RSI4.5
MACD3.8
OBV1.0
MA position2.2
Volume5.7
  • ▸Volume distribution (falling OBV)
  • ▸Below 200-MA but MA still rising (+4.3%/30d) — pullback in uptrend, not confirmed weakness

Sentiment

7.8/10data confidence 100%
ComponentSub-score
Analyst rating7.9
Price target10.0
erm sentiment5.0
  • ▸Light analyst coverage (8.0) — signal dampened
  • ▸Analyst upside: 244%

Insider

7.3/10data confidence 75%
ComponentSub-score
materiality5.0
holder change10.0
notable moves7.0
  • ▸Negligible insider buying — $20,008 (0.003% of mkt cap)
  • ▸Institutions accumulating

Peer rank

6.1/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank5.5
growth rank5.0
  • ▸Conservative debt levels

Technical

6.2/10data confidence 100%
ComponentSub-score
bollinger9.0
support resistance9.7
52w position0.0

Risk (lower is worse)

4.8/10data confidence 100%
ComponentSub-score
short interest1.9
days to cover2.1
volatility0.0
put call9.8
implied vol0.0
beta10.0
debt equity10.0
  • ▸High short interest justified: 16%
  • ▸High IV: 102%
  • ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

3.3/10data confidence 100%
ComponentSub-score
erm5.0
earnings history3.3
earnings timing5.0
surprise avg0.0

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (6)
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:110d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • MOMENTUM:3.4<4.5
Warning (1)
  • ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+25.1%
Downside
15.0%
Sizing output
AVOID

Setup— — No clear chart pattern; technical signals are mixed

EdgeNo clear edge — No clear edge identified

SuitabilitySpeculative — Drawdown -54% (>40% off 52w high), Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.4<4.5 outcome against Sentiment at 7.8 and asymmetric R:R of 0.00.

The strongest dimensions are Sentiment at 7.8, Insider at 7.3, and Technical at 6.2; the weakest are Quality at 1.6, Catalyst at 3.3, and Momentum at 3.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Single Asset Pipeline Concentration

    Trip ifA second clinical program accounts for more than 20% of pipeline spending.

  • P2Cash Burning Low Quality

    Trip ifQuality score rises above 4.0 from the current 1.6.

  • P3Predictable Loss Per Share

    Trip ifQuarterly EPS loss exceeds $0.30 per share from the current $0.19.

  • P4High Short Interest

    Trip ifShort interest falls below 8% from the current 16%.

  • P5Pullback In Uptrend

    Trip ifThe 200-day moving average slope falls below 0%/30d from the current +4.3%/30d.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › IMMX › Why this verdict